Modulation of lipoprotein(a) atherogenicity by high density lipoprotein cholesterol levels in middle-aged men with symptomatic coronary artery disease and normal to moderately elevated serum cholesterol

Journal of the American College of Cardiology

Volumn 30, Issue 6, 1997, Pages 1491-1499

  Cobbaert, Christa ^a   Jukema, J Wouter ^b   Zwinderman, Aeilko H ^b   Withagen, Adrie J A M ^c   Lindemans, Jan ^a   Bruschke, Albert V G ^c  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^c Dijkzigt Hospital ^*  (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

HIGH DENSITY LIPOPROTEIN CHOLESTEROL; ISOSORBIDE DINITRATE; LIPOPROTEIN A; PRAVASTATIN; TRIACYLGLYCEROL;

ADULT; ANGIOCARDIOGRAPHY; ARTICLE; ATHEROGENESIS; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY ARTERY DISEASE; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; HUMAN; HYPERCHOLESTEROLEMIA; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; REMISSION; RISK FACTOR; SUBLINGUAL DRUG ADMINISTRATION;

ANTICHOLESTEREMIC AGENTS; CHOLESTEROL; CHOLESTEROL, HDL; CORONARY ANGIOGRAPHY; CORONARY ARTERIOSCLEROSIS; DISEASE PROGRESSION; DOUBLE-BLIND METHOD; HUMANS; HYPERCHOLESTEROLEMIA; LIPOPROTEIN(A); MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PRAVASTATIN; PROSPECTIVE STUDIES; REFERENCE VALUES;

EID: 0030724884     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0735-1097(97)00353-7     Document Type: Article

References (48)

1. Dahlén GH. Lp(a) lipoprotein in cardiovascular disease [review]. Atherosclerosis 1994;108:111-26.
2. Scanu AM. Structural and functional polymorphism of lipoprotein(a): biological and clinical implications. Clin Chem 1995;41:170-2.
3. Armstrong VW, Cremer P, Eberle E, et al. The association between serum Lp(a) concentrations and angiographically assessed coronary atherosclerosis. Atherosclerosis 1986;62:249-57.
4. Dahlén GH, Guyton JR, Attar M, Farmer JA, Kautz JA, Gotto AM. Associations of levels of lipoprotein(a), plasma lipids and other lipoproteins with coronary artery disease documented by angiography. Circulation 1986; 74:758-65.
5. Rhoads GG, Dahlén GH, Berg K, Morton NE, Dannenberg AL. Lp(a) lipoprotein as a risk factor for myocardial infarction. JAMA 1986;256: 2540-4.
6. Durrington PN, Ishola M, Hunt L, Arrol S, Bhatnagar D. Apolipoprotein(a), A1 and B and parental history in men with early onset ischaemic heart disease. Lancet 1988;1:1070-3.
7. Hoefler G, Harnoncourt F, Paschke E, Mirtl W, Pfeiffer KH, Kostner GM. Lipoprotein(a): a risk factor for myocardial infarction. Arteriosclerosis 1988;8:398-401.
8. Sandkamp M, Funke H, Schulte H, Kohler E, Assmann G. Lipoprotein(a) is an independent risk factor for myocardial infarction at a young age. Clin Chem 1990;36:20-3.
9. Rosengren A, Wilhelmsen L, Eriksson E, Risberg B, Wedel H. Lipoprotein(a) and coronary heart disease: a prospective case-control study in a general population sample of middle-aged men. BMJ 1990;301:1248-51.
10. Seed M, Hoppichler F, Reaveley D, et al. Relation of lipoprotein(a) concentration and apolipoprotein(a) phenotype to coronary heart disease in patients with familial hypercholesterolemia. N Engl J Med 1990;322:1491-9.
11. Wiklund O, Angelin B, Olofsson SO, et al. Apolipoprotein(a) and ischaemic heart disease in familial hypercholesterolemia. Lancet 1990;335:1360-3.
12. Genest JJ, Martin-Munley SS, McNamara JR, et al. Familial lipoprotein disorders in patients with premature coronary artery disease. Circulation 1992;85:2025-33.
13. Cremer P, Nagel D, Labrot B, et al. Lipoprotein(a) as predictor of myocardial infarction in comparison to fibrinogen, LDL-cholesterol and other risk factors: results from the prospective Göttingen Risk Incidence and Prevalence Study (GRIPS). Eur J Clin Invest 1994;24:444-53.
14. Schaefer EJ, Lamon-Fava S, Jenner JL, et al. Lipoprotein (a) levels and the risk of coronary heart disease in men. JAMA 1994;271:999-1003.
15. Budde T, Fechtrup C, Bösenberg E, et al. Plasma Lp(a) levels correlate with the number, severity and length-extension of coronary lesions in male patients undergoing coronary arteriography for clinically suspected coronary atherosclerosis. Arterioscler Thromb 1994;14:1730-6.
16. Shah PK, Pasternak R. The role of lipids in restenosis following angioplasty. Curr Opin Lipidol 1993;4:310-3.
17. Averna MR, Barbagallo CM, Ocello S, et al. Lp(a) levels in patients undergoing aorto-coronary bypass surgery. Eur Heart J 1992;13:1405-9.
18. Jauhiainen M, Koskinen P, Ehnholm C, et al. Lipoprotein(a) and coronary heart disease risk: a nested case-control study of the Helsinki Heart Study participants. Atherosclerosis 1991;89:59-67.
19. Ridker PM, Hennekens CH, Meir J, Stampfer MJ. A prospective study of lipoprotein(a) and the risk of myocardial infarction. JAMA 1993;270:2195-9.
20. Simons L, Friedlander Y, Simons J, McCallum J. Lipoprotein(a) is not associated with coronary heart disease in the elderly: cross-sectional data from the Dubbo study. Atherosclerosis 1993;99:87-95.
21. Klausen IC, Beisiegel U, Menzel HJ, Rosseneu M, Nicaud V, Faergeman O, on behalf of the EARS group. Apo(a) phenotypes and Lp(a) concentrations in offspring of men with and without myocardial infarction: the EARS study. Arterioscler Thromb Vasc Biol 1995;15:1001-8.
22. Haffner SM, Moss SE, Klein BEK, Klein R. Lack of association between Lp(a) concentrations and coronary heart disease mortality in diabetes: the Wisconsin Epidemiologic Study of Diabetic Retinopathy. Metabolism 1992; 41:194-7.
23. Niemienen MS, Mattila KJ, Aalto-Setälä K, et al. Lipoproteins and their genetic variation in subjects with and without angiographically verified coronary artery disease. Arterioscler Thromb 1992;12:58-69.
24. Labeur C, De Bacquer D, De Backer G, et al. Plasma lipoprotein(a) values and severity of coronary heart disease in a large population of patients undergoing angiography. Clin Chem 1992;38:2261-6.
25. Berg K. Confounding results of Lp(a) lipoprotein measurements with some test kits. Clin Genet 1994;46:57-62.
26. Srinivasan SR, Dahlen GH, Jarpa RA, Webber LS, Berenson GS. Racial (black-white) differences in serum lipoprotein(a) distribution and their relation to parental myocardial infarction in children. Circulation 1991;84: 160-7.
27. Parra HJ, Luyeye I, Bouramoue C, Demarquilly C, Fruchart JC. Black-white differences in serum lipoprotein(a) levels. Clin Chim Acta 1987;167:27-31.
28. Lawn RM, Wade DP, Hammer RE, Chiesa G, Verstuyft JG, Rubin EM. Atherogenesis in transgenic mice expressing human apolipoprotein(a). Nature 1992;360:670-2.
29. Watts GF, Mandalia S, Slavin B, Brunt JNH, Coltart DJ, Lewis B. Metabolic determinants of the course of coronary artery disease in men. Clin Chem 1994;40:2240-6.
30. Marburger C, Hambrecht R, Niebauer J, et al. Association between lipoprotein(a) and progression of coronary artery disease in middle-aged men. Am J Cardiol 1994;73:742-6.
31. Terres W, Tatsis E, Pfalzer B, Beil U, Beisiegel U, Hamm CW. Rapid angiographic progression of coronary artery disease in patients with elevated lipoprotein(a). Circulation 1995;91:948-50.
32. Thompson GR, Maher VMG, Matthews S, et al. Familial hypercholesterolaemia regression study: a randomised trial of low-density-lipoprotein apheresis. Lancet 1995;345:811-6.
33. Jukema JW, Bruschke AVG, van Boven AJ, et al. Effects of lipid lowering by pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to moderately elevated serum cholesterol levels: the Regression Growth Evaluation Statin Study (REGRESS). Circulation 1995;91:2528-40.
34. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972;18:499-502.
35. Li KM, Wilcken DEL, Dudman NPB. Effect of serum lipoprotein(a) on estimation of low-density lipoprotein cholesterol by the Friedewald formula. Clin Chem 1994;40:571-3.
36. Wiebe DA, Westgard JO. Cholesterol - a model system to relate medical needs with analytical performance. Clin Chem 1993;39:1504-13.
37. Hoegee-de Nobel E, Voskuilen M, Briet E, Brommer EJP, Nieuwenhuizen W. A monoclonal antibody-based quantitative enzyme immunoassay for the determination of plasma fibrinogen concentrations. Thromb Haemostas 1988;60:415-8.
38. de Maat M. DNA polymorphisms of fibrinogen in men with symptomatic coronary heart disease. In: de Maat MP, editor. Regulation and Modulation of the Plasma Fibrinogen Level. Rotterdam: Erasmus University, 1995:177-87.
39. Superko HR, Krauss RM. Coronary artery disease regression: convincing evidence for the benefit of aggressive lipoprotein management. Circulation 1994;90:1056-69.
40. Scandinavian Simvastatin Survival Study Group. Baseline serum cholesterol and treatment effect in the Scandinavian Simvastatin Survival Study (4S). Lancet 1995;345:1274-5.
41. Thompson GR, Hollyer J, Waters DD. Percentage change rather than plasma level of LDL-cholesterol determines therapeutic response in coronary heart disease. Curr Opin Lipidol 1995;6:386-8.
42. Sacks FM, Pasternak RC, Gibson CM, Rosner B, Stone PH, for the Harvard Atherosclerosis Reversibility Project (HARP) Group. Effect on coronary atherosclerosis of decrease in plasma cholesterol concentration in normocholesterolaemic patients. Lancet 1994;344:1182-6.
43. MAAS Investigators. Effect of simvastatin on coronary atheroma: the Multicentre Anti-Atheroma Study (MAAS). Lancet 1994;344:633-8.
44. Maher VMG, Brown BG, Marcovina SM, Hillger LA, Zhao X, Albers JJ. Effects of lowering elevated LDL cholesterol on the cardiovascular risk of lipoprotein(a). JAMA 1995;274:1771-4.
45. Corsini A, Raiteri M, Soma MR, Bernini F, Fumagalli R, Paoletti R. Pathogenesis of atherosclerosis and the role of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors. Am J Cardiol 1995;76:21A-28A.
46. Waters D, Craven TE, Lespérance J. Prognostic significance of progression of coronary atherosclerosis. Circulation 1993;87:1067-75.
47. Buchwald H, Matts JP, Fitch LL, et al. for the Program on the Surgical Control of the Hyperlipidemias (POSCH) Group. Changes in sequential coronary arteriograms and subsequent coronary events. JAMA 1992;268: 1429-33.
48. Azen SP, Mack WJ, Cashin-Hemphill L, et al. Progression of coronary artery disease predicts clinical coronary events: long-term follow-up from the Cholesterol Lowering Atherosclerosis Study. Circulation 1996;93:34-41.